Back HBV Disease Progression

HBV Disease Progression

EASL 2012: Brivanib Did Not Improve Overall Liver Cancer Survival, but Did Show Anti-tumor Activity

The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumor activity, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.alt

Read more:

Statins May Reduce Liver Cancer Risk among People with Hepatitis B

Statins, a class of drugs used to manage elevated blood cholesterol, may also play a role in fighting hepatocellular carcinoma (HCC) -- a form of primary liver cancer -- among people with chronic hepatitis B, according to a report in the January 23, 2012, advance online edition of the Journal of Clinical Oncology.

Read more:

Hepatitis B and C Are Major Causes of Liver Cancer in U.S.

Chronic hepatitis C infection has replaced alcohol-related cirrhosis as a major cause of hepatocellular carcinoma (HCC, a form of primary liver cancer) in the U.S., according to a study by researchers at the Mayo Clinic in Rochester, MN. A related analysis found that among immigrants from Somalia, hepatitis B and C were both significant causes of liver cancer.

Read more:

High HBV Viral Load Linked to Greater Risk of Liver Cancer

Having a high blood level of hepatitis B virus (HBV) DNA increases the likelihood of developing hepatocellular carcinoma (HCC), a form of primary liver cancer, according to a study described in the January 13, 2012, Journal of Virology.

Read more:

MicroRNA Blood Test May Help Diagnose Early Liver Cancer in People with Hepatitis B

A set of 7 microRNAs in blood plasma accurately diagnosed hepatocellular carcinoma (HCC) and could distinguish between liver cancer and cirrhosis among people with chronic hepatitis B, according to study findings reported in the November 21, 2011, advance online edition of the Journal of Clinical Oncology.alt

Read more: